Cantor Fitzgerald Weighs in on Nuvalent FY2025 Earnings

Key Points

• Cantor Fitzgerald projects Nuvalent to report a FY2025 earnings per share of ($5.26), alongside a price target of $135.00, maintaining an "Overweight" rating.
• Nuvlalet's stock has a 52-week range with a low of $55.53 and a high of $104.81, currently trading at $92.52.
• Insider selling has been notable, with CEO James Richard Porter selling 27,000 shares at an average price of $90.63, reflecting a 9.78% decrease in his holdings.

Nuvalent, Inc. (NASDAQ:NUVL - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Nuvalent in a research note issued to investors on Thursday, October 16th. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will post earnings per share of ($5.26) for the year. Cantor Fitzgerald has a "Overweight" rating and a $135.00 price target on the stock. The consensus estimate for Nuvalent's current full-year earnings is ($3.86) per share. Cantor Fitzgerald also issued estimates for Nuvalent's FY2026 earnings at ($5.87) EPS.

NUVL has been the subject of a number of other research reports. Robert W. Baird lifted their price objective on Nuvalent from $105.00 to $112.00 and gave the stock an "outperform" rating in a research report on Wednesday, June 25th. Wedbush restated an "outperform" rating and issued a $115.00 price target on shares of Nuvalent in a report on Monday, September 8th. Weiss Ratings restated a "sell (d-)" rating on shares of Nuvalent in a report on Wednesday, October 8th. Stifel Nicolaus began coverage on Nuvalent in a report on Thursday. They issued a "buy" rating and a $115.00 price target for the company. Finally, The Goldman Sachs Group upgraded Nuvalent to a "strong-buy" rating in a report on Monday, June 30th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $120.00.

Nuvalent Trading Up 2.3%

Nuvalent stock opened at $92.52 on Monday. The stock has a market cap of $6.67 billion, a PE ratio of -18.88 and a beta of 1.30. The stock has a 50-day moving average price of $80.32 and a 200 day moving average price of $77.04. Nuvalent has a 52 week low of $55.53 and a 52 week high of $104.81.

Nuvalent (NASDAQ:NUVL - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($1.31) EPS for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.04). During the same period in the previous year, the firm posted ($0.88) earnings per share.

Institutional Trading of Nuvalent

A number of institutional investors have recently modified their holdings of the company. State Street Corp grew its holdings in shares of Nuvalent by 4.2% during the 2nd quarter. State Street Corp now owns 1,490,279 shares of the company's stock worth $113,708,000 after purchasing an additional 59,620 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Nuvalent by 11.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,450,602 shares of the company's stock worth $102,878,000 after acquiring an additional 152,692 shares in the last quarter. Wellington Management Group LLP lifted its position in Nuvalent by 12.3% during the 1st quarter. Wellington Management Group LLP now owns 1,442,384 shares of the company's stock worth $102,294,000 after acquiring an additional 157,809 shares in the last quarter. Braidwell LP lifted its position in Nuvalent by 39.8% during the 2nd quarter. Braidwell LP now owns 1,175,876 shares of the company's stock worth $89,719,000 after acquiring an additional 334,931 shares in the last quarter. Finally, Vestal Point Capital LP lifted its position in Nuvalent by 79.2% during the 1st quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company's stock worth $76,239,000 after acquiring an additional 475,000 shares in the last quarter. Hedge funds and other institutional investors own 97.26% of the company's stock.

Insider Transactions at Nuvalent

In other news, CEO James Richard Porter sold 27,000 shares of the business's stock in a transaction dated Thursday, October 16th. The stock was sold at an average price of $90.63, for a total transaction of $2,447,010.00. Following the completion of the sale, the chief executive officer owned 249,062 shares in the company, valued at approximately $22,572,489.06. The trade was a 9.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Deborah Ann Miller sold 12,376 shares of the business's stock in a transaction dated Thursday, October 16th. The stock was sold at an average price of $91.66, for a total value of $1,134,384.16. Following the sale, the insider owned 49,086 shares of the company's stock, valued at $4,499,222.76. The trade was a 20.14% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 191,771 shares of company stock worth $16,298,129 over the last 90 days. Company insiders own 10.20% of the company's stock.

Nuvalent Company Profile

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.